- Home
- CTO vs GRAL Comparison
CTO vs GRAL Comparison
Compare CTO & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- GRAL
- Stock Information
- Founded
- CTO 1902
- GRAL 2016
- Country
- CTO United States
- GRAL United States
- Employees
- CTO N/A
- GRAL N/A
- Industry
- CTO Real Estate Investment Trusts
- GRAL
- Sector
- CTO Real Estate
- GRAL
- Exchange
- CTO Nasdaq
- GRAL NYSE
- Market Cap
- CTO 589.6M
- GRAL 1.3B
- IPO Year
- CTO N/A
- GRAL N/A
- Fundamental
- Price
- CTO $17.90
- GRAL $46.72
- Analyst Decision
- CTO Strong Buy
- GRAL Buy
- Analyst Count
- CTO 3
- GRAL 3
- Target Price
- CTO $22.33
- GRAL $31.50
- AVG Volume (30 Days)
- CTO 374.3K
- GRAL 1.6M
- Earning Date
- CTO 07-29-2025
- GRAL 08-12-2025
- Dividend Yield
- CTO 8.59%
- GRAL N/A
- EPS Growth
- CTO N/A
- GRAL N/A
- EPS
- CTO N/A
- GRAL N/A
- Revenue
- CTO $132,203,000.00
- GRAL $130,711,000.00
- Revenue This Year
- CTO $20.11
- GRAL $19.52
- Revenue Next Year
- CTO $8.51
- GRAL $20.37
- P/E Ratio
- CTO N/A
- GRAL N/A
- Revenue Growth
- CTO 17.48
- GRAL 30.47
- 52 Week Low
- CTO $16.12
- GRAL $12.33
- 52 Week High
- CTO $21.15
- GRAL $63.99
- Technical
- Relative Strength Index (RSI)
- CTO 43.15
- GRAL N/A
- Support Level
- CTO $17.10
- GRAL N/A
- Resistance Level
- CTO $17.71
- GRAL N/A
- Average True Range (ATR)
- CTO 0.36
- GRAL 0.00
- MACD
- CTO -0.06
- GRAL 0.00
- Stochastic Oscillator
- CTO 47.50
- GRAL 0.00
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.